Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$134.33

-0.6 (-0.44%)

06:33
08/29/18
08/29
06:33
08/29/18
06:33

Indian panel wants J&J to pay compensation over recalled implants, Reuters says

A government panel in India has recommended that Johnson & Johnson pay compensation of at least $28,500 to each Indian patient who suffered from artificial hip implants the company recalled eight years ago, Reuters reports, citing the panel. The company, which recalled the implants after data suggested they failed at a higher-than-expected rate, agreed to pay about $2.5B in 2013 to settle thousands of lawsuits from those in the U.S. who claimed they were injured by the implants and paid $2M to Indian patients for repeat surgeries as well as roughly $250,000 in related diagnostic costs under its ASR reimbursement program. Reference Link

  • 04

    Sep

  • 05

    Sep

  • 12

    Sep

  • 13

    Sep

  • 28

    Oct

JNJ Johnson & Johnson
$134.33

-0.6 (-0.44%)

08/27/18
OPCO
08/27/18
NO CHANGE
Target $60
OPCO
Outperform
Portola Pharmaceuticals price target lowered to $60 from $70 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Portola Pharmaceuticals (PTLA) to $60 from $70 after results of the MARINER trial of Johnson & Johnson (JNJ) rivaroxaban in medically ill patients missed the primary endpoint. While the analyst sees MARINER results as positive for Portola's Bevyxxa due to less competition, highlighting the favorable product profile, he anticipates additional efforts remaining in order to gain access and drive demand. Olson reiterates an Outperform rating on Portola's shares.
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
08/27/18
WBLR
08/27/18
NO CHANGE
WBLR
Outperform
Mariner failure removes potential Portola competition, says William Blair
William Blair analyst Matt Phipps says that while the failure of Johnson & Johnson's (JNJ) Mariner trial removes potential competition Portola Pharmaceuticals' (PTLA) Bevyxxa, which is positive, "significant work" is still needed to gain adoption of Bevyxxa in the United States. As such, the Mariner results do not significantly alter the near-term headwinds for Bevyxxa, Phipps tells investors in a research note. The analyst believes getting beyond the Mariner presentation allows investors to focus on the opportunity for Andexxa, which he still thinks is "significant." He points out that Portola remains on track to file the prior approval supplement for the second-generation manufacturing process of Andexxa in the coming days, which would provide sufficient supply for 1,000 hospitals in the United States and expansion into Europe. Phipps keeps an Outperform rating on Portola Pharmaceuticals, which is up 5% to $29.60 in premarket trading.
08/27/18
MSCO
08/27/18
NO CHANGE
MSCO
Equal Weight
Portola may be up 'somewhat' on Xarelto trial failure, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted the failure of Johnson & Johnson's (JNJ)MARINER study, which was examining Xarelto, a competing anticogulant to Portola's (PTLA) BevyxXa. MARINER's failure to demonstrate a statistically significant result of reducing symptomatic VTE or death due to VTE is expected by Harrison to send Portola shares up "somewhat," but he believes most investors had already lowered their expectations for the BevyxXa franchise after the Q2 report, making the impact modest. He maintains an Equal Weight rating on Portola shares, which are up 3% to $29 per share in early trading.

TODAY'S FREE FLY STORIES

MAT

Mattel

$10.93

-0.25 (-2.24%)

14:55
12/18/18
12/18
14:55
12/18/18
14:55
Options
Mattel put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

14:55
12/18/18
12/18
14:55
12/18/18
14:55
General news
Treasury Action: Treasuries are vulnerable to a knee jerk selloff Wednesday »

Treasury Action:…

MU

Micron

$34.82

0.93 (2.74%)

14:49
12/18/18
12/18
14:49
12/18/18
14:49
Options
Micron options imply 12.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 08

    Jan

MLM

Martin Marietta

$177.29

1.74 (0.99%)

14:46
12/18/18
12/18
14:46
12/18/18
14:46
Hot Stocks
Martin Marietta takes action after 'say on pay' vote, reviewing executive pay »

In connection with Martin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$103.68

0.7 (0.68%)

, AMD

AMD

$19.57

0.74 (3.93%)

14:36
12/18/18
12/18
14:36
12/18/18
14:36
Periodicals
Microsoft next Xbox console is codenamed Anaconda, Verge reports »

Microsoft's (MSFT)…

MSFT

Microsoft

$103.68

0.7 (0.68%)

AMD

AMD

$19.57

0.74 (3.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 03

    Mar

  • 04

    Mar

BIIB

Biogen

$293.41

-19.81 (-6.32%)

, RHHBY

Roche

$0.00

(0.00%)

14:32
12/18/18
12/18
14:32
12/18/18
14:32
Recommendations
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks »

Bernstein analyst Aaron…

BIIB

Biogen

$293.41

-19.81 (-6.32%)

RHHBY

Roche

$0.00

(0.00%)

MYL

Mylan

$29.00

0.15 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 18

    Mar

DUK

Duke Energy

$87.77

-0.31 (-0.35%)

14:32
12/18/18
12/18
14:32
12/18/18
14:32
Hot Stocks
Former Duke Energy chairman and CEO Jim Rogers dies »

Jim Rogers, the former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFMS

Conformis

$0.45

-0.0215 (-4.54%)

14:31
12/18/18
12/18
14:31
12/18/18
14:31
Hot Stocks
Conformis enters common stock purchase agreement with Lincoln Park Capital Fund »

Conformis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$16.60

0.18 (1.10%)

14:30
12/18/18
12/18
14:30
12/18/18
14:30
Options
Hefty call spreads in First Data for the second time in three trading days »

Hefty call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

BIIB

Biogen

$293.35

-19.87 (-6.34%)

, MYL

Mylan

$29.02

0.17 (0.59%)

14:29
12/18/18
12/18
14:29
12/18/18
14:29
Recommendations
Biogen, Mylan analyst commentary  »

Piper says Biogen…

BIIB

Biogen

$293.35

-19.87 (-6.34%)

MYL

Mylan

$29.02

0.17 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APEN

Apollo Endosurgery

$3.57

0.08 (2.29%)

14:27
12/18/18
12/18
14:27
12/18/18
14:27
Recommendations
Apollo Endosurgery analyst commentary  »

Craig-Hallum says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
12/18/18
12/18
14:20
12/18/18
14:20
General news
Canada CPI preview »

Canada CPI preview:…

TCEHY

Tencent

$0.00

(0.00%)

, DIS

Disney

$109.75

-0.88 (-0.80%)

14:18
12/18/18
12/18
14:18
12/18/18
14:18
Periodicals
'PUBG' on mobile has as many total users as 'Fortnite,' Verge reports »

The mobile version of…

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$109.75

-0.88 (-0.80%)

KKR

KKR

$19.89

0.09 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 11

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/18/18
12/18
14:17
12/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/18/18
12/18
14:16
12/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$6.72

-0.39 (-5.49%)

14:05
12/18/18
12/18
14:05
12/18/18
14:05
Options
McDermott call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$163.24

-0.19 (-0.12%)

14:02
12/18/18
12/18
14:02
12/18/18
14:02
Hot Stocks
General Dynamics unit awarded Department of Education contract »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

APHA

Aphria

$5.87

0.43 (7.90%)

, TLRY

Tilray

$76.52

10.63 (16.13%)

14:00
12/18/18
12/18
14:00
12/18/18
14:00
Hot Stocks
Citron touts cannabis name Aphria again, sees shares above $8 by year-end »

Shares of Aphria (APHA)…

APHA

Aphria

$5.87

0.43 (7.90%)

TLRY

Tilray

$76.52

10.63 (16.13%)

ACB

Aurora Cannabis

$5.57

0.03 (0.54%)

MO

Altria Group

$51.40

-0.97 (-1.85%)

NVS

Novartis

$85.56

-0.24 (-0.28%)

CRON

Cronos Group

$11.50

0.375 (3.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 07

    Feb

STZ

Constellation Brands

$172.45

-3.61 (-2.05%)

13:55
12/18/18
12/18
13:55
12/18/18
13:55
Options
Constellation Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MU

Micron

$34.81

0.92 (2.71%)

, UMC

UMC

$1.81

-0.005 (-0.28%)

13:50
12/18/18
12/18
13:50
12/18/18
13:50
On The Fly
Fly Intel: What to watch for in Micron's earnings report »

Micron (MU) is scheduled…

MU

Micron

$34.81

0.92 (2.71%)

UMC

UMC

$1.81

-0.005 (-0.28%)

INTC

Intel

$48.04

0.95 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 04

    Jan

  • 07

    Jan

  • 08

    Jan

VOD

Vodafone

$19.88

-0.13 (-0.65%)

13:48
12/18/18
12/18
13:48
12/18/18
13:48
Periodicals
Vodafone preparing to remove PwC as auditor, Sky News reports »

Vodafone is preparing to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$1,057.23

30.69 (2.99%)

, GOOG

Alphabet

$1,046.01

28.41 (2.79%)

13:40
12/18/18
12/18
13:40
12/18/18
13:40
Periodicals
Search engine startup claims Google still blocking competition, TechCrunch says »

The European Commission…

GOOGL

Alphabet Class A

$1,057.23

30.69 (2.99%)

GOOG

Alphabet

$1,046.01

28.41 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

KMX

CarMax

$60.38

0.11 (0.18%)

13:40
12/18/18
12/18
13:40
12/18/18
13:40
Options
7X average daily option volume in CarMax driven by an earnings hedge »

7X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

  • 31

    Jan

  • 01

    Feb

BIDU

Baidu

$169.94

0.03 (0.02%)

13:35
12/18/18
12/18
13:35
12/18/18
13:35
Hot Stocks
Unity Technologies, Baidu partner to develop autonomous vehicle simulation »

Unity Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$131.11

2 (1.55%)

13:32
12/18/18
12/18
13:32
12/18/18
13:32
Periodicals
J&J settles woman's talc cancer case for over $1.5M, Bloomberg reports »

Johnson & Johnson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 27

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.